A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Subjects
Latest Information Update: 20 Nov 2023
At a glance
- Drugs ABBV 903 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 09 Nov 2023 Status changed from recruiting to discontinued (strategic considerations).
- 15 Sep 2023 Status changed from not yet recruiting to recruiting.
- 28 Aug 2023 New trial record